Ruxolitinib S enantiomer

Research use only, not for human use.

The chirality of Ruxolitinib (INCB-018424), which is a potent, selective, orally active JAK1/JAK2 inhibitor.

The chirality of Ruxolitinib (INCB-018424), which is a potent, selective, orally active JAK1/JAK2 inhibitor with IC50 of 3.3/2.8 nM, respectively.

RT-PCR Cell Line:Human small airway epithelial cells (SAECs) Concentration:10?μM Incubation Time:12 hours Result:Suppressed IFNβ-induced expression of ISG, IFIT, and IFITM.

Animal Model:Female wild-type C57BL/6J or Nes-gfp27 mice with myeloproliferative neoplasms (MPNs) in peripheral blood Dosage:30 mg/kg (in 0.5% hydroxypropyl methylcellulose after solubilisation in DMSO) Administration: Oral gavage; twice per day separated 10-12 h for 8 weeks Result:Reduced haematopoietic cell expansion in MPN but it did not rescue bone marrow (BM) mesenchymal stem cells (MSCs).

S-Ruxolitinib | INCB-018424 S enantiomer

Angiogenesis

JAK

Chk2|JAK1|JAK2|JAK3|Tyk2

Inflammation/Immunology

——

941685-37-6

306.365

C17H18N6

>98% (HPLC)

10 mM in DMSO

N#CC[C@@H](C1CCCC1)N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2

1H-Pyrazole-1-propanenitrile, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βS)-

(-20℃)

With Ice Pack

≥ 2 years